SHERIDAN, WYOMING – May 9, 2025 – Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions industry, has reported its financial results for the first quarter of 2025. Despite a slight dip in global net sales, the company remains confident in its ability to drive long-term growth and innovation. The results reflect challenges faced in certain areas, including slower deal closures in Enabling Technology, but also showcase the company’s strong positioning in the U.S. spine business.
First Quarter Financial Highlights
- Worldwide Net Sales: $598.1 million, a decrease of 1.4% compared to Q1 2024.
- U.S. Net Sales: Increased by 0.2% compared to Q1 2024.
- International Net Sales: Decreased by 7.7% as reported, or 4.6% on a constant currency basis.
- GAAP Net Income: $75.5 million, showing strong year-over-year improvement.
- GAAP Diluted EPS: $0.54, compared to a loss of $0.05 in Q1 2024.
- Non-GAAP Diluted EPS: $0.68, an 8.5% increase from the prior year.
- Free Cash Flow: Record Q1 free cash flow of $141.2 million, with net cash provided by operating activities totaling $177.3 million.
Dan Scavilla, President and CEO of Globus Medical, emphasized the company’s resilience, stating, “Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and timing of international distributor orders. However, we are encouraged by the strong performance in April and are confident in our ability to drive above-market revenue growth moving forward. Our commitment to innovation and advancing patient care remains central to our strategy.”
Debt-Free Status and Strong Cash Flow
One of the key achievements for Globus Medical in Q1 2025 was the complete repayment of the $450 million debt incurred from the NuVasive merger. Keith Pfeil, COO and CFO, highlighted the significance of this milestone: “During the quarter, we returned to a debt-free status, while achieving record free cash flow. This positions us well to continue our investment in internal manufacturing capabilities, which is essential for sustainable long-term growth.”
The company’s continued focus on scaling its operations is evident from its strategic investments in machinery and equipment, aiming to increase production capacity. These efforts are designed to support the company’s long-term vision of growth in the musculoskeletal solutions market.
Revised Full-Year 2025 Guidance
Looking ahead, Globus Medical has reaffirmed its revenue guidance for 2025, forecasting a range of $2.80 billion to $2.90 billion. However, the company has slightly revised its non-GAAP diluted EPS guidance to $3.00 to $3.30, down from the previously projected range of $3.10 to $3.40. This adjustment reflects the current quarter’s performance and market conditions but does not alter the company’s long-term growth outlook.
Strategic Focus on Innovation
Globus Medical remains committed to enhancing patient outcomes by providing innovative musculoskeletal solutions. The company continues to prioritize investments in research and development to bring forward clinically advanced products that meet the evolving needs of healthcare providers and surgeons. As part of this strategy, the company’s Enabling Technology division remains a critical area of focus, with new product launches expected to drive future growth.
“Despite short-term challenges, our strategic investments in technology and innovation will position us for continued success,” concluded Scavilla. “We remain steadfast in our mission to improve patient care and deliver superior shareholder value.”
About Globus Medical, Inc.
Globus Medical is a leading musculoskeletal solutions company that designs, develops, and commercializes a broad range of spinal surgery products. The company is focused on advancing the quality of care for patients worldwide through innovation, clinical evidence, and cutting-edge technologies.
For more information about Globus Medical and its product offerings, visit www.globusmedical.com.